TEVA — Teva Pharmaceutical Industries Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.21 | ||
| PEG Ratio (f) | 0.43 | ||
| EPS Growth (f) | 16.93% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.6% | ||
| Return on Equity | -15.28% | ||
| Operating Margin | 2.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16,887 | 16,659 | 15,878 | 14,925 | 15,846 | 16,395.41 | 16,993.86 | -3.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +19.4 | -63.83 | +298.66 | -28.47 | +32.97 | +82.81 | +12.87 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Directors
- Sol Barer NEC (73)
- Kaare Schultz PRE (60)
- Eliyahu Kalif CFO (48)
- Galia Inbar CHO
- Richard Daniell EVP (54)
- Sven Dethlefs EVP (52)
- Eric Drape EVP (59)
- Hafrun Fridriksdottir EVP (59)
- Mark Sabag EVP (50)
- Eli Shani EVP
- David Stark EVP (52)
- Amir Weiss SVP (44)
- Rosemary Crane IND (61)
- Amir Elstein IND (65)
- Jean-Michel Halfon IND (69)
- Gerald Lieberman IND (74)
- Roberto Mignone IND (49)
- Perry Nisen IND (65)
- Nechemia Peres IND (62)
- Ronit Satchi-Fainaro IND (49)
- Janet Vergis IND (56)
- Tal Zvi Zaks IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 13th, 1944
- Public Since
- January 1st, 1951
- No. of Shareholders
- 1,934
- No. of Employees
- 35,001
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 1,133,050,214
- Address
- 124 Dvora Hanevi'a St., TEL AVIV-YAFO, 6944020
- Web
- https://www.tevapharm.com/
- Phone
- +972 39148213
- Contact
- Ran Meir
- Auditors
- Kesselman & Kesselman
Latest News for TEVA
Upcoming Events for TEVA
Similar to TEVA
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 22:40 UTC, shares in Teva Pharmaceutical Industries are trading at $17.12. This share price information is delayed by 15 minutes.
Shares in Teva Pharmaceutical Industries last closed at $17.12 and the price had moved by +80.97% over the past 365 days. In terms of relative price strength the Teva Pharmaceutical Industries share price has outperformed the S&P500 Index by +38.23% over the past year.
The overall consensus recommendation for Teva Pharmaceutical Industries is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreTeva Pharmaceutical Industries does not currently pay a dividend.
Teva Pharmaceutical Industries does not currently pay a dividend.
Teva Pharmaceutical Industries does not currently pay a dividend.
To buy shares in Teva Pharmaceutical Industries you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.12, shares in Teva Pharmaceutical Industries had a market capitalisation of .
Here are the trading details for Teva Pharmaceutical Industries:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: TEVA
Based on an overall assessment of its quality, value and momentum Teva Pharmaceutical Industries is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Teva Pharmaceutical Industries is $21.25. That is 24.12% above the last closing price of $17.12.
Analysts covering Teva Pharmaceutical Industries currently have a consensus Earnings Per Share (EPS) forecast of $2.47 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Teva Pharmaceutical Industries. Over the past six months, its share price has underperformed the S&P500 Index by -8.33%.
As of the last closing price of $17.12, shares in Teva Pharmaceutical Industries were trading +5.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Teva Pharmaceutical Industries PE ratio based on its reported earnings over the past 12 months is 6.21. The shares last closed at $17.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Teva Pharmaceutical Industries' management team is headed by:
- Sol Barer - NEC
- Kaare Schultz - PRE
- Eliyahu Kalif - CFO
- Galia Inbar - CHO
- Richard Daniell - EVP
- Sven Dethlefs - EVP
- Eric Drape - EVP
- Hafrun Fridriksdottir - EVP
- Mark Sabag - EVP
- Eli Shani - EVP
- David Stark - EVP
- Amir Weiss - SVP
- Rosemary Crane - IND
- Amir Elstein - IND
- Jean-Michel Halfon - IND
- Gerald Lieberman - IND
- Roberto Mignone - IND
- Perry Nisen - IND
- Nechemia Peres - IND
- Ronit Satchi-Fainaro - IND
- Janet Vergis - IND
- Tal Zvi Zaks - IND